Safety and Efficacy of Baricitinib in Patients Receiving Conventional Synthetic Disease-Modifying Antirheumatic Drugs or Corticosteroids

ConclusionsBaricitinib was efficacious regardless of concomitant use of csDMARDs or corticosteroids; the incidence of adverse events was similar across all groups of patients.FundingEli Lilly and Company and Incyte Corporation.
Source: Rheumatology and Therapy - Category: Rheumatology Source Type: research